¼¼°èÀÇ ¿ø³» °¨¿° Ä¡·á(HAI) ½ÃÀå : ±âȸ¿Í ÃËÁø¿äÀÎ, ¾÷°è µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)
Hospital Acquired Infections Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
»óǰÄÚµå : 1620441
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 130 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¿ø³» °¨¿° Ä¡·á(HAI) ½ÃÀåÀº 2023³â¿¡ 126¾ï ´Þ·¯·Î Æò°¡µÇ°í 2024-2032³â¿¡ °ÉÃÄ CAGR 3.2%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¼ºÀåÀº ÀÇ·á °ü·Ã °¨¿°ÀÇ ¹ß»ý·ü »ó½Â, ȯÀÚ ÄÉ¾î °³¼±¿¡ ´ëÇÑ ÁÖ¸ñÀÇ ³ô¾ÆÁü, HAIÀÇ ¸¸¿¬À» ¾ïÁ¦Çϱâ À§ÇÑ Á¤ºÎÀÇ Àû±ØÀûÀÎ ´ëó°¡ Å« ¿äÀÎÀÔ´Ï´Ù. ±×¸®°í HAIÀÇ ¸¸¿¬Àº ÀÔ¿ø ȯÀÚ Áõ°¡, ȯÀÚÀÇ ÀÔ¿ø ±â°£ÀÇ ¿¬Àå, ħ½ÀÀû ÀÇ·á±â±â »ç¿ë Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ »ó½ÂÇϰí ÀÖ½À´Ï´Ù. ¿ä·Î °¨¿°Áõ, Æó·Å, Ç÷·ù °¨¿°Áõ µîÀÇ ÀϹÝÀûÀÎ °¨¿°ÁõÀÌ È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼Ç ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ½À´Ï´Ù. °Ô´Ù°¡, ¸é¿ª °áÇÌ È¯ÀÚ Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ °¨¿°¿¡ ´ëÇÑ °¨¼ö¼ºÀÌ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

¸¶¾à À¯Çüº°·Î º¼ ¶§ ½ÃÀåÀº Ç×±ÕÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, Ç×Áø±ÕÁ¦ ¹× ±âŸ ¾àÁ¦·Î ±¸ºÐµË´Ï´Ù. ƯÈ÷ ÀÇ·á ȯ°æ¿¡¼­ Ç×»ýÁ¦ ³»¼º ¹ÚÅ׸®¾Æ°¡ Áõ°¡ÇÔ¿¡ µû¶ó HAI Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. Ç×±ÕÁ¦´Â MRSA³ª Ŭ·Î½ºÆ®¸®µã µðÇǽǰú °°Àº ÀúÇ×¼º ¹ÚÅ׸®¾Æ °¨¿°¿¡ ´ëóÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÏ¸ç °­·ÂÇÑ Ä¡·á ÁßÀç°¡ ÇÊ¿äÇÕ´Ï´Ù.

Åõ¿©°æ·ÎÀÇ °üÁ¡¿¡¼­ ½ÃÀåÀº Á¤¸Æ³»(IV)¿ä¹ý, °æ±¸¿ä¹ý, ±¹¼Ò¿ä¹ý, ÈíÀÔ¿ä¹ýÀ¸·Î ³ª´¹´Ï´Ù. Á¤¸Æ³» Åõ¿©´Â Ç÷·ù·Î Á÷Á¢ ¾à¹°À» ½Å¼ÓÇÏ°Ô Àü´ÞÇÒ ¼ö Àֱ⠶§¹®¿¡ º´¿ø °í¸® °æ°è¿¡¼­ ¼±È£µÇ´Â ¹æ¹ýÀÔ´Ï´Ù. À̰ÍÀº »ý¸íÀ» À§ÇùÇÏ´Â »óŸ¦ ´Ù·ç±â À§ÇØ ½Å¼ÓÇÑ Ä¡·á°¡ ÇÊ¿äÇÑ ½É°¢ÇÑ °¨¿°ÀÇ °ü¸®¿¡ ƯÈ÷ Áß¿äÇÕ´Ï´Ù. HAI ÁßÁõ ȯÀÚ¸¦ °ü¸®ÇÏ´Â ÃÖ¼±ÀÇ ¼±ÅÃÀ̵Ǿú½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ³â 2023³â
¿¹Ãø³â 2024-2032³â
½ÃÀÛ±Ý¾× 126¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 164¾ï ´Þ·¯
CAGR 3.2%

ºÏ¹Ì ½ÃÀåÀº 2023³â¿¡ 47¾ï ´Þ·¯¸¦ Â÷ÁöÇϸç, 2024-2032³â¿¡ °ÉÃÄ CAGR 2.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. µû¶ó¼­ HAIÀÇ À§ÇèÀÌ ³ô¾ÆÁö°í °¨¿° ´ëÃ¥ÀÌ ÇʼöÀûÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå »ê¾÷ ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : ¾àÁ¦ À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : °¨¿° À¯Çüº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤¡¤¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Hospital Acquired Infections Therapeutics Market was valued at USD 12.6 billion in 2023 and is expected to grow at a CAGR of 3.2% from 2024 to 2032. This growth is largely driven by the rising incidence of healthcare-associated infections, the increasing focus on improved patient care, and active government efforts to control the spread of HAIs. The prevalence of HAIs is climbing due to several factors, including higher hospital admissions, extended patient stays, and the growing use of invasive medical devices. Common infections such as urinary tract infections, pneumonia, and bloodstream infections are contributing to the demand for effective therapeutic solutions. Additionally, the growing population of immunocompromised patients further increases the susceptibility to these infections.

By drug type, the market is segmented into antibacterial, antiviral, antifungal, and other drugs. In 2023, antibacterial drugs dominated the market with a revenue of USD 9.2 billion. These drugs are essential for treating HAIs, especially with the increasing presence of antibiotic-resistant bacteria in healthcare environments. Antibacterial drugs are critical in addressing infections caused by resistant strains like MRSA and Clostridium difficile, which require potent therapeutic interventions.

In terms of administration routes, the market is divided into intravenous (IV), oral, topical, and inhalation therapies. The IV segment led the market, generating USD 5.7 billion in 2023. IV administration is the preferred method in hospital settings, as it ensures the rapid delivery of medications directly into the bloodstream. This is particularly important for managing severe infections, where quick therapeutic action is needed to combat life-threatening conditions. The high efficacy and immediate impact of IV-administered drugs make it the go-to option for managing critical HAI cases.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$12.6 Billion
Forecast Value$16.4 Billion
CAGR3.2%

The North American market accounted for USD 4.7 billion in 2023 and is expected to grow at a CAGR of 2.5% between 2024 and 2032. The demand for HAI therapeutics in the region is driven by the high rate of infections and the presence of an advanced healthcare system. North America's vast network of hospitals and healthcare facilities increases the risk of HAIs, making infection control measures essential. The presence of leading pharmaceutical companies and ongoing research and development efforts also contribute to the development and availability of advanced treatment options, further fueling market growth.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Infection Type, 2021 - 2032 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

Chapter 9 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â